Forte Biosciences, Inc. (FBRX) announced the pricing of a public offering of 5,630,450 shares of its common stock at $12.00 per share.
The gross proceeds from the offering are expected to be approximately $75 million.
The offering is anticipated to close on or about June 26, 2025.
Forte Biosciences plans to use the net proceeds for working capital and other general corporate purposes.
This includes financing clinical and preclinical development of its product candidate as well as other research activities.
